Yuki Kageyama to Awards and Prizes
This is a "connection" page, showing publications Yuki Kageyama has written about Awards and Prizes.
Connection Strength
0.188
-
A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL). BMC Urol. 2023 Mar 06; 23(1):33.
Score: 0.188